IP Library › Granted Patent US 11,129,874
Granted Patent B2
US 11,129,874 · App. 16/117,960 · Granted Sep 28, 2021

Nucleic acids encoding FGF21-Fc fusion proteins

Inventors: Brian R. Boettcher (Winchester, MA); Shari Lynn Caplan (Lunenburg, MA); Douglas S. Daniels (Arlington, MA); Norio Hamamatsu (Belmont, MA); Stuart Licht (Cambridge, MA); Stephen Craig Weldon (Leominster, MA)
Assignee: Novartis AG
A61K38/1825A61K45/06C07K14/50A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,129,874
App. No.
16/117,960
Granted
Sep 28, 2021
Kind
B2
Abstract

The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.

Claims (12)

1. A nucleic acid coding for a fusion protein comprising a fibroblast growth factor 21 (FGF21) variant and an Fc region, wherein the FGF21 variant comprises an amino acid sequence with at least 95% identity to the full length hFGF21 sequence SEQ ID NO:1, and comprises at least the following mutations relative to SEQ ID NO:1: Q55C, G148C, K150R, P158S, S195A, P199G, and G202A, and one of R105K and A109T.

2. A vector comprising the nucleic acid according to claim 1 .

3. A host cell comprising the vector of claim 2 .

4. A method of producing a fusion protein, wherein the method comprises culturing the host cell of claim 3 .

5. The nucleic acid of claim 1 , wherein the nucleic acid codes for a fusion protein comprising the amino acid sequence of SEQ ID NO: 10, 11, 12, or 13.

6. A vector comprising the nucleic acid according to claim 5 .

7. A host cell comprising the vector of claim 6 .

8. A method of producing a fusion protein, wherein the method comprises culturing the host cell of claim 7 .

9. The nucleic acid of claim 1 , wherein the nucleic acid codes for a fusion protein comprising the amino acid sequence of SEQ ID NO: 11.

10. A vector comprising the nucleic acid according to claim 9 .

11. A host cell comprising the vector of claim 10 .

12. A method of producing a fusion protein, wherein the method comprises culturing the host cell of claim 11 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2019
From: BOETTCHER, BRIAN R.; CAPLAN, SHARI L.; DANIELS, DOUGLAS S.; HAMAMATSU, NORIO; LICHT, STUART; WELDON, STEPHEN CRAIG
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 048171/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2019
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
To: NOVARTIS AG
Reel/Frame 048171/0851 →
Continuity (5)
Continuation 14987338 · Jan 4, 2016
Division 14630206 · Feb 24, 2015
Division 13626194 · Sep 25, 2012
Provisional Application 61539280 · Sep 26, 2011
Related Publication 20180369332A1 · Dec 27, 2018
Cited By (3)
US 12,491,231 US 12,668,774 US 12,686,847